<DOC>
	<DOCNO>NCT02291055</DOCNO>
	<brief_summary>Part A : ( ADXS11-001 + MEDI4736 Combination Therapy ) determine safety tolerability combination identify RP2D . Part B : Phase 2 design randomize subject 1:1 either MEDI4736 alone MEDI4736+ADXS11-001 subject fail least 1 prior systemic treatment recurrent/persistent metastatic cervical cancer .</brief_summary>
	<brief_title>Phase 1-2 Study ADXS11-001 MEDI4736 Alone Combo In Cervical HPV+ Head &amp; Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Have histological diagnosis squamous cell cancer head &amp; neck confirmation HPV positivity squamous , nonsquamous , adenosquamous , carcinoma adenocarcinoma cervix HPV positivity require 2 . Have measurable and/or evaluable disease RECIST 1.1 3 . Have ECOG performance status 0 1 4 . Have adequate organ function define protocol . : 1 . Has prior Grade â‰¥3 immunerelated adverse event ( irAE ) receive immunotherapy , include antiCTLA4 treatment , unresolved irAE &gt; Grade 1 . 2 . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior Day 1 trial treatment . 3 . Has concurrent chemotherapy , immunotherapy , biologic hormonal therapy invasive malignancy within 2 year . Concurrent use hormone noncancerrelated condition ( eg , insulin diabetes hormone replacement therapy ) acceptable . 4 . Has active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . 5 . Has implant medical device ( ) pose high risk colonization and/or easily remove ( e.g. , prosthetic joint , artificial heart valve , pacemaker , orthopedic screw ( ) , metal plate ( ) , bone graft ( ) , exogenous implant ( ) ) . NOTE : More common device prosthetics include arterial venous stent , dental breast implant , venous access device ( e.g. , PortaCath Mediport ) permit . Sponsor must contact prior consent subject device and/or implant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>